Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000885725
$46.01
+3.37% · delayed ~15 min
Last price from Oct 22, 2026
$67.90B market value
From BOSTON SCIENTIFIC CORP's FY2025 10-K, filed Feb 17, 2026 · read the filing
BOSTON SCIENTIFIC makes medical devices and equipment. It took in $20.07B last year, which makes it a large company. Of every dollar it sells, about 14 cents is left as profit.
The financial picture is led by profitability, growth, debt and accounting.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Strong finances across the board.
From BOSTON SCIENTIFIC CORP's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$1.85B → $2.89B
Earnings per share
$1.26 → $1.96
Cash
$414.0M → $1.97B
Revenue
$16.75B → $20.07B
Measured against FY2024, from the 10-K filed Feb 17, 2026
Improved: +56.7%
$1.85B to $2.89BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
BSX rose 3.37% on the latest quote. The average Health Care company tracked here moved +1.57%, and the S&P 500 −1.04%. That is 1.8 points above its sector and 4.4 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 6% a year for the next 10 years. Over the last 10 years it grew by about 23% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 14 cents of every dollar of sales as profit, earning $2.89B last year.
Yes, quickly. Sales grew 19.9% last year.
No. At its current cash flow it could clear its debt in about 2.1 years. For every $1 it owes, it owns $2.25 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $2.89B and generated $4.53B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 17, 2026Filing for FY2025 | FY202410-K · Feb 18, 2025Filing for FY2024 | FY202310-K · Feb 20, 2024Filing for FY2023 | FY202210-K · Feb 20, 2024Filing for FY2022 | FY202110-K · Feb 20, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | +19.9% |
| Cost of revenue | $6.22B | $5.26B | $4.34B | $3.96B | $3.71B | +18.3% |
| Gross profit | $13.85B | $11.49B | $9.90B | $8.73B | $8.18B | +20.6% |
| Gross marginGross profit ÷ revenueWhat is this? | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% | +0.4 pts |
| Selling, general and administrative | $6.89B | $5.98B | $5.19B | $4.52B | $4.36B | +15.1% |
| Operating income | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B | +38.8% |
| Operating marginOperating income ÷ revenueWhat is this? | 18.0% | 15.5% | 16.5% | 13.0% | 10.1% | +2.5 pts |
| Interest expense | $349.0M | $305.0M | $265.0M | $470.0M | $341.0M | +14.4% |
| Income before tax | $3.38B | $2.28B | $1.99B | $1.14B | $1.08B | +48.3% |
| Net income | $2.89B | $1.85B | $1.59B | $698.0M | $1.04B | +56.7% |
| Net marginNet income ÷ revenueWhat is this? | 14.4% | 11.0% | 11.2% | 5.5% | 8.8% | +3.4 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $1.96 | $1.26 | $1.11 | $0.4892 | $0.7346 | +55.7% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| BSXBOSTON SCIENTIFIC CORP · this page | 10.0/10 | 8/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 1,171 shares
Holds 8,459 shares after this filing.
Had shares withheld to cover taxes — 567 shares at $48.37 ($27.4K)
Holds 7,892 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join · Reported another event
Read the filingHad a director or senior officer leave or join
Read the filingWrite down why you are following BOSTON SCIENTIFIC CORP, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
1 Stock Under $50 with Exciting Potential and 2 We Question
Yahoo ·
Boston Scientific (BSX) Stock May Be 44% Undervalued As Neuromodulation Growth Builds
Yahoo ·
Australia Bionic Devices Market Size, Share, Growth, and Forecast 2026-2034 Featuring Profiles of Cochlear, Medtronic Australasia, Edwards Lifesciences Australia, Baxter Int'l, Boston Scientific Corp., Abiomed Australia, Abbott Labs
Yahoo ·
Global Gastric Device Market Report 2026-2032: Size, Share, Trends and Forecast for Gastric Bands and Balloons | GLP-1 Drugs Leave Gastric Balloons and Bands Struggling for Growth
Yahoo ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from BSX's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 17, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 10.0 | 8/9 | 10-K, filed Feb 17, 2026 |
| FY2024 | 8.0 | 6/9 | 10-K, filed Feb 18, 2025 |
| FY2023 | 7.0 | 8/9 | 10-K, filed Feb 20, 2024 |
| FY2022 | 6.0 | 7/9 | 10-K, filed Feb 23, 2023 |
| FY2021 | 7.0 | 8/9 | 10-K, filed Feb 23, 2022 |
| FY2020 | 4.0 | 4/9 | 10-K, filed Feb 23, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
3.10
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.51
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +55.7%
$1.26 to $1.96Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +374.6%
$414.0M to $1.97BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +19.9%
$16.75B to $20.07BSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +20.6%
$11.49B to $13.85BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +38.8%
$2.60B to $3.61BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +3.4 pts
11.0% to 14.4%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +38.3%
$2.65B to $3.66BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: +24.2%
$8.97B to $11.14BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +2.5 pts
15.5% to 18.0%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Changed: +10.9%
$790.0M to $876.0MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 3, 2026 — read it.
Improved: +43.8%
$819.0M to $1.18BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +3.0 pts
67.7% to 70.7%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +5.5 pts
16.2% to 21.6%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +7.5%
$5.06B to $5.44BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +12.4%
$3.42B to $3.85BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +13.8%
$795.0M to $905.0MNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +14.6%
$0.54 to $0.62Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 3, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: −9.1 pts
25.7% to 16.6%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -62.9%
$1.45B to $539.0MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: -32.4%
$1.34B to $905.0MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: -31.7%
$0.90 to $0.62Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +6.5%
$3.61B to $3.85BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +7.0%
$1.10B to $1.18BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +1.3 pts
69.5% to 70.7%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 4% and 8%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 37 analysts covering this company, as of . Their views, not this site's.
Of 37 analysts publishing on this company, 10 say strong buy, 19 say buy and 8 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 17.9x — investors pay $17.9 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 19.9% |
| 14.4% |
| 23.48x |
| 0.80x |
| ABTABBOTT LABORATORIES | 9.0/10 | 6/9 | 5.7% | 14.7% | 27.25x | 0.66x |
|---|
| ISRGINTUITIVE SURGICAL INC | 10.0/10 | 7/8 | 20.5% | 28.4% | 55.19x | 0.14x |
|---|
| SYKSTRYKER CORP | 9.0/10 | 6/9 | 11.2% | 12.9% | 36.10x | 1.13x |
|---|
| BDXBECTON DICKINSON & CO | 7.0/10 | 6/9 | 8.2% | 7.7% | 34.09x | 1.18x |
|---|
| EWEdwards Lifesciences Corp | 9.0/10 | 6/9 | 11.5% | 17.7% | 48.73x | 0.32x |
|---|
| IDXXIDEXX LABORATORIES INC /DE | 9.0/10 | 8/9 | 10.4% | 24.6% | 42.64x | 1.09x |
|---|
| RMDRESMED INC | 9.0/10 | 8/9 | 9.9% | 26.9% | 23.96x | 0.36x |
|---|
| Median of peers | 9.0/10 | — | 10.4% | 17.7% | 36.10x | 0.66x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Bought on the open market — 2,040 shares at $49.22 ($100.4K)
Holds 13,784 shares after this filing.
Reported a transaction — 2,930 shares at $51.19 ($150.0K)
Holds 2,930 shares after this filing.
Reported a transaction — 9,908 shares at $50.46 ($500.0K)
Holds 9,908 shares after this filing.
Bought on the open market — 2,100 shares at $47.59 ($99.9K)
Holds 17,160 shares after this filing.
Bought on the open market — 186,240 shares at $48.33 ($9.0M)
Holds 1,590,024 shares after this filing.
Reported a transaction — 22,119 shares at $48.43 ($1.1M)
Holds 22,119 shares after this filing.
Bought on the open market — 1,042 shares at $48.07 ($50.1K)
Holds 14,920 shares after this filing.
Bought on the open market — 140 shares at $48.59 ($6.8K)
Holds 15,060 shares after this filing.
Bought on the open market — 5,000 shares at $45.48 ($227.4K)
Holds 30,359 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Disclosed a material cybersecurity incident
Reported another event
Read the filingQuarterly report for Q2 FY2026
Revenue +7.5% · Operating margin +5.5 pts · Operating income +43.8% — against Q2 FY2025
Read the filingPublished results
Read the filingAnnounced restructuring or exit costs
Read the filingReported another event
Read the filingReported another event
Read the filingAmended its charter or changed its financial year · Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +11.6% · Operating margin +1.4 pts · Profit +99.3% — against Q1 FY2025
Read the filingPublished results
Read the filingReported another event
Read the filingProxy statement for a shareholder meeting
Read the filingSigned a material agreement · Terminated a material agreement · Took on a direct financial obligation
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure · Reported another event
Read the filingAnnual report for FY2025
Revenue +19.9% · Operating margin +2.5 pts · Profit +56.7% — against FY2024
Read the filingHad a director or senior officer leave or join
Read the filingPublished results
Read the filingSigned a material agreement
Read the filingStryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Yahoo ·
Primary sources and further research